Manufacturers Explore Shared Audits in Quest to Control Global Supply Chain
This article was originally published in The Gold Sheet
Sharing audits could be the key to controlling the global supply chain, Rx-360 consortium members agreed at their first meeting this month. With suppliers inundated by audit requests in the wake of last year's heparin incident, many have started charging customers for hosting audits, they said. Shared audits are seen as cheaper and better. Rx-360-led audits prove the most popular of three proposed audit-sharing systems. The others involved sharing subscription audits or individual drug makers' audits, the least popular option. Rx-360 also would scan for emerging adulteration risks. Tiers 2 and 3 suppliers should be monitored too, Beroe says. Pfizer upgrades three key aspects of its supplier management program. Parexel, Novartis note stepped-up FDA enforcement with a new focus on supply chain management. Advice given on how to audit - and how not to.
You may also be interested in...
The US FDA managed to issue 94 drug GMP warning letters last year despite the pandemic, with fewer expected for 2021. Top issue areas included lack of sterility assurance, nitrosamine impurities, poor data integrity and basic GMP failures.
Pharmaceutical manufacturers should have already begun serializing products and verifying saleable returns to comply with DSCSA, says FDA official who also asserted that licensing standards for wholesale distributors and third-party logistics providers will be forthcoming. This rule is already six years overdue under a DSCSA mandated timeline.
The US FDA wants manufacturers and compounding facilities to test drug products for methanol in alcohol ingredients, and responds to reports of fatal methanol poisonings of consumers who ingested alcohol-based based hand sanitizers.